Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cytogenetics in the genomic era
Publication date: Available online 4 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Isabel Granada, Laura Palomo, Neus Ruiz, Mar Mallo, Francesc Solé (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 5, 2020 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: June 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - May 24, 2020 Category: Hematology Source Type: research

Index
Publication date: June 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - May 24, 2020 Category: Hematology Source Type: research

Establishing specific response criteria for MDS/MPN - Getting closer to reality?
Publication date: Available online 7 May 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Matthew T. Villaume, Michael R. Savona (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - May 7, 2020 Category: Hematology Source Type: research

Juvenile myelomonocytic leukemia – A bona fide RASopathy syndrome
Publication date: Available online 29 April 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Terra Lasho, Mrinal M. Patnaik (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - April 29, 2020 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: March 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - March 3, 2020 Category: Hematology Source Type: research

Index
Publication date: March 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - March 3, 2020 Category: Hematology Source Type: research

Measurable disease evaluation in patients with myeloma
Publication date: Available online 4 February 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Mikhail RoshalAbstractRecent years saw significant breakthroughs in treatment of multiple myeloma. Durable remissions are now seen in a significant proportion of patients with the previously uniformly incurable and progressive disease. Yet because of deep suppression of the neoplastic myeloma clones by the newer therapies, older disease monitoring techniques are insufficient to distinguish between the patients at high risk of imminent relapse and those in whom durable remission is expected. This review briefly ...
Source: Best Practice and Research Clinical Haematology - February 5, 2020 Category: Hematology Source Type: research

Multiple Myeloma: Current Advances and Future Directions
Publication date: Available online 5 February 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Ola Landgren (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - February 5, 2020 Category: Hematology Source Type: research

Genomic profiling of multiple myeloma: new insights and modern technologies
Publication date: Available online 27 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Malin Hultcrantz, Venkata Yellapantula, Even H. RustadAbstractAdvances in technologies for genomic profiling, primarily with next generation sequencing, have lead to a better understanding of the complex genomic landscape in multiple myeloma. Integrated analysis of whole genome, exome and transcriptome sequencing has lead to new insights on disease drivers including translocations, copy number alterations, somatic mutations, and altered gene expression. Disease progression in multiple myeloma is largely driven ...
Source: Best Practice and Research Clinical Haematology - January 28, 2020 Category: Hematology Source Type: research

High-risk smoldering myeloma versus early detection of multiple myeloma: current models, goals of therapy, and clinical implications
Publication date: Available online 25 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Chutima Kunacheewa, Elisabet E. ManasanchAbstractMultiple myeloma, a bone marrow cancer, is preceded by precursor stages called monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Over the past few years, highly effective and safe therapies have been made available to treat multiple myeloma. This represents a major breakthrough and has major therapeutic implications. Treatment for multiple myeloma has evolved to include treatment of precursor stages (early treatment) as these therapie...
Source: Best Practice and Research Clinical Haematology - January 25, 2020 Category: Hematology Source Type: research

Modern treatments and future directions for newly diagnosed multiple myeloma patients
Publication date: Available online 23 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Sydney Lu, Assistant Attending, Myeloma ServiceAbstractOver the course of the past decade-plus, the therapy of newly diagnosed multiple myeloma has seen incredible advances in the domains of diagnostic evaluation, active medical therapy, and response evaluation. This manuscript reviews the evaluation and management of newly diagnosed active multiple myeloma, with a focus on major clinical trials and IMWG recommendations. The paper describes a current approach for the initial evaluation and workup of a patient w...
Source: Best Practice and Research Clinical Haematology - January 23, 2020 Category: Hematology Source Type: research

The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies—back to the future!
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Dickran Kazandjian, Alexander Dew, Elizabeth HillAbstractState of the art treatment for myeloma involves using 3-drug combinations incorporating immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Clinical trials for 4-drug combinations incorporating monoclonal antibodies added to IMiD and PI based backbones are underway. Recent retrospective analyses show that patients who attain MRD negativity have similar long term outcomes regardless of early or delayed high dose melphalan with autologous stem c...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research

Monitoring minimal residual disease in the bone marrow using next generation sequencing
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Even H. Rustad, Eileen M. BoyleAbstractAchieving minimal residual disease (MRD) negativity in the bone marrow is one of the strongest prognostic factors in multiple myeloma. Consequently, MRD testing is routinely performed in clinical trials and moving towards standard of care. This review focuses on the role of next generation sequencing (NGS) of tumor-specific immunoglobulin V(D)J sequences for MRD tracking. The immunoglobulin variable regions are ideal targets for tracking, because every tumor cell shares an...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research

MDS/MPN-RS-T justified Inclusion as a unique disease entity?
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Guillermo Montalban-Bravo, Guillermo Garcia-ManeroABSTRACTMyelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a disease entity characterized by anemia, bone marrow dysplasia with ring sideroblasts and persistent thrombocytosis ≥450 x109/L with proliferation of large and morphologically atypical megakaryocytes. Although initially recognized by the World Health Organization only as a provisional entity, next generation sequencing has identified recurr...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research